Manufacturers focused on developing and marketing products for the clinical treatment of obesity must contend with a dynamic space in which many existing alternatives — devices, drugs and surgery — are actively competing for caseload. This is a challenge, even in a growth market that is expanding faster than waistlines. New devices (gastric restriction, malabsorption, emptying, and appetite suppression) continue to enter the market, while sometimes very serious complications are causing regulatory, market, clinical and consumer backlash that is serving to reign in rampant growth. New drugs are tantalizingly near to upending the market balance, but even recent regulatory efforts to reestablish rapprochement with drug companies by the FDA's willingness to reconsider drugs like Contrave, Lorcaserin and Qnexa have not allayed industry's and the investment community's concerns that the obesity drug opportunity is uncomfortably suspect.
Medical devices continue to serve the purpose and provide clinical options in the fast of burgeoning demand.
Below, drawn from "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019" (MedMarket Diligence Report #S835), is a partial table (less than half in published version), with key data obscured for clients' benefit, illustrating the number of different devices under development for management of obesity.
Companies with Obesity Devices on Market or in Development, 2011
Source: MedMarket Diligence, LLC; Report #S835.